# US 8,278,412 B2 · Polypeptide, nucleic acid molecule encoding it and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,412 B2
- Document ID: US8278412B2
- Status: Granted
- Kind: B2
- Application number: 12/373,048
- Filed: 2007-07-10
- Published: 2009-11-26
- Granted: 2012-10-02
- Earliest claimed: 2006-07-10
- Assignees: Hong Zheng
- Inventors: Hong Zheng
- Web page: https://patentgrep.com/patent/US8278412B2

## CPC

- C07K 14/47: from mammals
- A61P 35/00: Antineoplastic agents
- C12N 9/6445: {Kallikreins (3.4.21.34; 3.4.21.35)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino acids at 1-30 positions, amino acids at 50-80 positions and amino acids at 17-200 positions of the amino acid sequence shown in SEQ ID NO:3. The nucleic acid molecule encoding the polypeptide, recombinant vectors and host cells comprising the nucleic acid molecule are also provided. The polypeptide and the nucleic acid molecule encoding it can be used for preparing reagents, kits or devices for diagnosing the diseases characterized by EECP expression and pharmaceutical compositions for preventing or treating the diseases characterized by EECP expression by increasing or inhibiting EECP expression and/or activity.

## Claims

### Claim 1

An isolated polypeptide comprising an antigenic epitope of the amino acid sequence of SEQ ID NO: 3, wherein the isolated polypeptide has a sequence of amino acids at positions 16 to 32, 1 to 30, 50 to 80, or 170 to 200 of SEQ ID NO: 3, and the isolated polypeptide is from 10 to 50 amino acids in length.

### Claim 2

A method of preparing an antibody against an isolated polypeptide, the method comprising:
providing a polypeptide containing an antigenic epitope of the amino acid sequence of SEQ ID NO: 3, and
raising an antibody against the polypeptide,
wherein the isolated polypeptide has a sequence of amino acids at positions 16 to 32, 1 to 30, 50 to 80, or 170 to 200 of SEQ ID NO: 3, and the isolated polypeptide is from 10 to 50 amino acids in length.

### Claim 3 (depends on 2)

The method of claim 2, wherein the antibody is a monoclonal antibody or polyclonal antibody.

### Claim 4 (depends on 1)

The isolated polypeptide of claim 1, wherein the isolated polypeptide has a sequence of amino acids at positions 16 to 32 of SEQ ID NO: 3.

### Claim 5 (depends on 1)

The isolated polypeptide of claim 1, wherein the isolated polypeptide has a sequence of amino acids at positions 1 to 30 of SEQ ID NO: 3.

### Claim 6 (depends on 1)

The isolated polypeptide of claim 1, wherein the isolated polypeptide has a sequence of amino acids at positions 50 to 80 of SEQ ID NO: 3.

### Claim 7 (depends on 1)

The isolated polypeptide of claim 1, wherein the isolated polypeptide has a sequence of amino acids at positions 170 to 200 of SEQ ID NO: 3.

### Claim 8 (depends on 2)

The method of claim 2, wherein the isolated polypeptide has a sequence of amino acids at positions 16 to 32 of SEQ ID NO: 3.

### Claim 9 (depends on 2)

The method of claim 2, wherein the isolated polypeptide has a sequence of amino acids at positions 1 to 30 of SEQ ID NO: 3.

### Claim 10 (depends on 2)

The method of claim 2, wherein the isolated polypeptide has a sequence of amino acids at positions 50 to 80 of SEQ ID NO: 3.

### Claim 11 (depends on 2)

The method of claim 2, wherein the isolated polypeptide has a sequence of amino acids at positions 170 to 200 of SEQ ID NO: 3.

### Claim 12 (depends on 3)

The method of claim 3, wherein the isolated polypeptide has a sequence of amino acids at positions 16 to 32 of SEQ ID NO: 3.

### Claim 13 (depends on 3)

The method of claim 3, wherein the isolated polypeptide has a sequence of amino acids at positions 1 to 30 of SEQ ID NO: 3.

### Claim 14 (depends on 3)

The method of claim 3, wherein the isolated polypeptide has a sequence of amino acids at positions 50 to 80 of SEQ ID NO: 3.

### Claim 15 (depends on 3)

The method of claim 3, wherein the isolated polypeptide has a sequence of amino acids at positions 170 to 200 of SEQ ID NO: 3.
